Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type.

@article{Birkmayer1996CoenzymeNA,
  title={Coenzyme nicotinamide adenine dinucleotide: new therapeutic approach for improving dementia of the Alzheimer type.},
  author={J{\"o}rg G. D. Birkmayer},
  journal={Annals of clinical and laboratory science},
  year={1996},
  volume={26 1},
  pages={1-9}
}
The Coenzyme nicotinamide adenine dinucleotide (NADH) has been used as medication in 17 patients suffering from dementia of the Alzheimer type in an open label trial. In all patients evaluated so far, an improvement in their cognitive dysfunction was observed. Based on the minimental state examination, the minimum improvement was 6 points and the maximum improvement 14 points with a mean value of 8.35 points. The improvement on the basis of the global deterioration scale (GDS) was a minimum of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Antioxidant Therapies for Alzheimer's Disease

Oxidative medicine and cellular longevity • 2012
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Monoaminergic neurotransmitters in brains of morbus Alzheimer patients

D Storga, K Vrecko, Birkmayer JGD, G Reibnegger
Neurosci Lett • 1996

Nicotinamide Adenine Dinucleotide ( NADH ) as Medication for Parkinson ’ s disease experience with 415 patients

W Birkmayer, Birkmayer JGD, +3 authors E Ott
New Trends Clin Neuropharmacol • 1990

Nicotinamide adenine dinucleotide ( NADH ) as medication for Parkinson ’ s disease . Experience with 415 Patients

W Birkmayer, Birkmayer JDG, +3 authors E Ott
New Trends Clin Neuropharmacol • 1990

Similar Papers

Loading similar papers…